Tempus AI, Inc. has seen a notable increase in its stock price, driven by positive developments in the AI drug discovery sector and significant research presentations.
Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM) is rising today, gaining 4.15% as investors react positively to recent announcements regarding the company's participation in the European Society for Medical Oncology Congress and the broader growth forecast for AI in drug discovery.
Advertisement
Tempus AI, Inc. Class A Common Stock
TEM.US
TEM.US
Tempus AI, Inc. Class A Common Stock
WealthAwesomeMarket cap
$13.80B
52W high
$104.32
52W low
$40.77
1W change
-6.98%
Beta
3.72
Analyst Price Targets
Based on 12 analysts covering TEM · as of Sep 23, 2026
Wall Street analysts forecast TEM stock price to fall 10.4% over the next 12 months.
Consensus
Buy3.83 / 5.00
Avg. Target
C$68.56
-10.4% Upside
Previously C$68.18 on Sep 17, 2026
Current Price
C$76.50
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TEM's historical volatility
30-Day Vol
86.4%
Annualized
90-Day Vol
86.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$91.46
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$81.19 | C$60.26 – C$109.40 |
| 60 trading days | C$86.17 | C$56.52 – C$131.38 |
| 90 trading days | C$91.46 | C$54.56 – C$153.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The growth in Tempus' stock reflects investor optimism about the company's role in the rapidly expanding AI healthcare market, particularly in oncology.
4.15% Increase
Tempus' stock price rose to CA$79.81, reflecting strong investor confidence amid promising industry forecasts.
Bull case
Tempus' acceptance of 13 abstracts for presentation at a prestigious oncology congress highlights its innovative capabilities and commitment to advancing cancer treatment. This could lead to more partnerships and increased revenue.
Bear case
Despite the positive momentum, Tempus faces challenges like a lack of profitability and competition in the AI healthcare space, which could impact its long-term growth.
Positive Industry Trends
Advertisement
The global AI in drug discovery market is projected to grow significantly, with estimates ranging from $19.89 billion in 2025 to as much as $160.49 billion by 2035. This growth is driven by advancements in generative AI and predictive analytics, areas where Tempus is actively involved.
Key Research Presentations
Tempus recently announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology Congress 2026. These presentations will showcase the company's innovative AI-enabled technologies and their applications in improving cancer treatment outcomes.
Market Response
Following these announcements, investors have reacted positively, pushing Tempus' stock price up by 4.15% to CA$79.81. This uptick reflects growing confidence in the company's future prospects as it continues to expand its role in precision medicine.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
